SG Americas Securities LLC Buys 280,199 Shares of Urogen Pharma $URGN

SG Americas Securities LLC lifted its position in Urogen Pharma (NASDAQ:URGN) by 20.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,657,846 shares of the company’s stock after purchasing an additional 280,199 shares during the period. SG Americas Securities LLC’s holdings in Urogen Pharma were worth $29,808,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Invesco Ltd. increased its holdings in Urogen Pharma by 21.1% during the 4th quarter. Invesco Ltd. now owns 27,066 shares of the company’s stock worth $634,000 after purchasing an additional 4,711 shares during the period. Susquehanna Portfolio Strategies LLC purchased a new stake in shares of Urogen Pharma in the 4th quarter worth $641,000. Superstring Capital Management LP grew its position in shares of Urogen Pharma by 717.1% during the 4th quarter. Superstring Capital Management LP now owns 718,354 shares of the company’s stock worth $16,824,000 after buying an additional 630,442 shares in the last quarter. Orbimed Advisors LLC grew its position in shares of Urogen Pharma by 27.1% during the 4th quarter. Orbimed Advisors LLC now owns 875,487 shares of the company’s stock worth $20,504,000 after buying an additional 186,487 shares in the last quarter. Finally, Opaleye Management Inc. purchased a new position in shares of Urogen Pharma during the fourth quarter valued at $6,286,000. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Stock Up 0.5%

Shares of URGN opened at $35.15 on Wednesday. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -12.78 and a beta of 1.59. Urogen Pharma has a twelve month low of $12.73 and a twelve month high of $35.58. The company has a 50 day moving average of $27.67 and a two-hundred day moving average of $23.12.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $50.96 million for the quarter, compared to analyst estimates of $44.83 million. On average, sell-side analysts expect that Urogen Pharma will post -0.98 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. D. Boral Capital reissued a “buy” rating and set a $33.00 target price on shares of Urogen Pharma in a research report on Tuesday, March 31st. Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a research report on Tuesday, June 2nd. LADENBURG THALM/SH SH initiated coverage on shares of Urogen Pharma in a report on Monday, May 11th. They issued a “buy” rating and a $43.00 price target for the company. Finally, Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Urogen Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $39.50.

Insider Buying and Selling at Urogen Pharma

In related news, insider Mark Schoenberg sold 5,222 shares of the business’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $27.30, for a total transaction of $142,560.60. Following the transaction, the insider directly owned 139,763 shares in the company, valued at $3,815,529.90. The trade was a 3.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.80% of the stock is owned by insiders.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.